Clik here to view.
Beyond Glivec : Balancing innovation and public health
I’d like to introduce a guest column by Dr Kristina Lybecker, Associate Professor of Economics at Colorado College in Colorado Springs. Kristina is an economist with a PhD from the University of...
View ArticleClik here to view.
Guest column : Are “prizes” to reward drug R&D a viable alternative to patents?
Given the intense public debate over access to and pricing of patented medicines, academics, policymakers, lawyers, and others have begun to think creatively about what it is that actually incentivises...
View ArticleClik here to view.
Global R&D convention: Pipe dream?
Frustration with the status quo of the patent system and its inability to address the growing needs of developing countries has inspired the development of a new innovation paradigm, a global research...
View ArticleClik here to view.
Guest column : Is “evergreening” of drug patents all bad?
A recent article in Health Affairs considers how secondary patenting can extend market exclusivity and delay generic competition. Amin and Kesselheim examine two key anti-HIV drugs Norvir and Kaletra....
View ArticleClik here to view.
Guest column : Indian patent rulings and pharma strategies
The Indian government made several critical patent decisions over the past year. Their impact on the Indian intellectual property (IP) landscape is still evolving, with important implications for IP...
View ArticleClik here to view.
Guest column : Indian patent rulings and impact on emerging economies
Recent Indian patent rulings, as well as those to come, are changing the intellectual property rights (IPR) landscape for emerging economies. They are watched with keen interest by other developing...
View ArticleClik here to view.
Guest column : Implications of the #Januvia patent lawsuit in India
The banning of diabetes drug pioglitazone (now looking set to be revoked) has put Merck’s patented drug sitagliptin or Januvia back into the limelight in India. Critics of the ban have highlighted the...
View ArticleClik here to view.
India and drug #patents : The Ghost of #Glivec haunts #Sovaldi
Apothecurry welcomes back guest columnist Dr Kristina Lybecker. Her latest column is an elegantly simple “where the rubber hits the road” exposition of the recent rejection of patents on US biopharma...
View ArticleClik here to view.
Guest column : The UN High-Level Panel on #accesstomedicines is a wolf in...
In 2015, the United Nations Secretary-General Ban Ki-moon convened a High-Level Panel on Access to Medicines. Its charge was to recommend solutions to the fallaciously described “policy incoherence...
View Article
